Owkin, the AI company dedicated to solving the complexity of biology, has announced the launch of its specialized biological AI agent, Pathology Explorer, integrated with Anthropic’s Claude for Healthcare and Life Sciences (HCLS). This marks the first time a highly advanced, interoperable AI agent trained on multimodal patient data is made available to a broad audience in healthcare and life sciences through the Model Context Protocol (MCP). Pathology Explorer is designed to analyze complex, multi-source patient data—including digital pathology slides, genomic information, and clinical records—enabling deeper insights into disease mechanisms and treatment responses. By leveraging the MCP, the agent can seamlessly interact with various AI models and data systems, bringing state-of-the-art AI agent capabilities to the healthcare sector. The launch comes as part of Owkin’s broader mission to advance biological discovery through AI. The company is building a new infrastructure for AI-driven biological research, aiming to achieve what it calls “biological superintelligence.” This vision is being accelerated through strategic partnerships, including a recent collaboration with NVIDIA to enhance OwkinZero, its large-scale biological reasoning model, using NVIDIA’s cutting-edge AI ecosystem, including the Nemotron family of open models and the NeMo framework for performance, scalability, and security. Owkin’s latest innovation follows the successful international validation of BRCAura, an AI-powered tool for identifying germline BRCA1/2 mutations directly from digital pathology slides of breast cancer samples. The results, published in a recent study, demonstrate the potential of AI to support early detection and personalized treatment planning, particularly in a disease that remains the leading cause of cancer-related deaths among women worldwide. The integration of Pathology Explorer with Claude for HCLS will allow researchers, clinicians, and biopharma teams to access powerful AI tools directly within their workflows, enabling faster, more accurate analysis of complex biological data. The agent is now available to users through the HCLS platform, marking a significant step forward in democratizing access to advanced AI in healthcare and life sciences. Owkin continues to expand its ecosystem, positioning itself at the forefront of AI-driven biological discovery and innovation.